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Selective 5-HT7 receptor agonists LP 44 and LP 
211 elicit an analgesic effect on formalin-induced 
orofacial pain in mice
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TKHPRVW UHFHQWO\ LGHQWL¿HG VHURWRQLQ +7 UHFHSWRU LV WKH +7 UHFHSWRU 7KHantinociceptive effects of a 5-HT7 receptor agonist have been shown in neuropathic and 
LQÀDPPDWRU\DQLPDOPRGHOVRISDLQ$UHFHQWVWXG\GHPRQVWUDWHGWKHIXQFWLRQDOH[SUHVVLRQ
of 5-HT7 receptors in the substantia gelatinosa (SG) of the trigeminal subnucleus caudalis, 
which receives and processes orofacial nociceptive inputs. Objective: To investigate the 
antinociceptive effects of pharmacological activation of 5-HT7 receptors on orofacial pain 
in mice. Material and Methods: Nociception was evaluated by using an orofacial formalin 
test in male Balb-C mice. Selective 5-HT7 receptor agonists, LP 44 and LP 211 (1, 5, and 
10 mg/kg), were given intraperitoneally 30 min prior to a formalin injection. A bolus of 10 
μl of 4% subcutaneous formalin was injected into the upper lip of mice and facial grooming 
behaviors were monitored. The behavioral responses consisted of two distinct periods, the 
early phase corresponding to acute pain (Phase I: 0–12 min) and the late phase (Phase 
II: 12–30 min). Results: LP 44 and LP 211 (1, 5, and 10 mg/kg) produced an analgesic 
effect with reductions in face rubbing time in both Phase I and Phase II of the formalin test. 
Conclusion: Our results suggest that 5-HT7 receptor agonists may be promising analgesic 
drugs in the treatment of orofacial pain.
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INTRODUCTION
Orofacial pain treatments remain an important 
consideration in dental care and patient 
management. Patients often evaluate a clinician’s 
ability by their success or failure in pain control. 
Dental pain management requires a multifactorial 
approach that includes a combination of good 
treatment procedures and the use of appropriate 
analgesics12.
The majority of drugs used to manage pain in 
'HQWLVWU\DUHQRQVWHURLGDODQWLLQÀDPPDWRU\GUXJV
(NSAIDs) and opioid analgesics10. Opioid analgesics 
are controlled substances and have many serious 
adverse side effects such as drug abuse, nausea, 
and vomiting3. Thus, most acute dental pain can 
be managed with the proper NSAID. However, 
VXEDFXWHDQGFKURQLFGHQWDOSDLQSUHVHQWGLI¿FXOWLHV
due to the problems associated with the long term 
use of NSAIDs, which may be associated with 
VLJQL¿FDQWVLGHHIIHFWVLQFOXGLQJJDVWURLQWHVWLQDODQG
renal diseases17. Thus, it is necessary to discover 
new drugs and new target molecules to relieve 
severe dental pain.
It is well known that serotonin plays a crucial 
role in the regulation of pain via its interaction with 
5-HT receptors2. Previous studies have reported 
roles for 5-HT1A, 5-HT2, and 5-HT3 receptors in 
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pain regulation9,14,16. The 5-HT7 receptor is the most 
UHFHQWO\LGHQWL¿HG+7UHFHSWRUDQGDYDULHW\RI
studies have provided evidence that 5-HT7 receptor 
agonists produce antinociceptive effects in a variety 
RILQÀDPPDWRU\DQGQHXURSDWKLFSDLQPRGHOV,Q
a recent study, Yang, et al.20 (2014) indicate that 
5-HT7 receptors are functionally expressed in a 
subpopulation of the substantia gelatinosa of the 
trigeminal subnucleus caudalis, which receives 
and processes orofacial nociceptive inputs. To our 
NQRZOHGJHQRVWXGLHVKDYHHYDOXDWHGWKHHI¿FDF\
of 5-HT7 receptor agonists on orofacial pain. In this 
study, we investigated the effects of selective 5-HT7 
receptor agonists, LP 44 and LP 211, on orofacial 
pain using a formalin model in mice.
MATERIAL AND METHODS
Selection of the experimental group
Experiments were performed in the Drug 
Research and Development Laboratory of 
Pharmacology Department. Female Balb-C (25–32 
g) mice were used. Mice were housed in a well-
ventilated room at 22±2°C under a 12 h light: 
12 h dark cycle and with free access to food and 
water. The experimental group consisted of 6–8 
mice. Nociception was evaluated by using orofacial 
formalin test. Each of the subjects were allowed to 
separately provide adaptation within 30 min in the 
observation room in which a 30x30x30 cm Plexiglas 
box was placed with mirrors with a 45 degree angle 
to see unobstructed views of the orofacial region. 
The protocol was approved by the Animal Care and 
Use Committee.
Drugs
Selective 5-HT7 receptor agonists, LP 44 and 
LP 211, were used for this study. While LP 44 was 
dissolved in distilled water, LP 211 was dissolved in 
5% dimethyl sulfoxide (DMSO). LP 44 and LP 211 
(1, 5, and 10 mg/kg) were given intraperitoneally 
(i.p.) in a volume of 5 ml/kg, 30 minutes prior to 
the formalin injection. Vehicle was given to the 
control groups.
Orofacial formalin test and the assessment 
of antinociceptive effects
Orofacial nociception was evaluated using 
formalin as previously described11. A bolus of 4% 
formalin (10 μl) was subcutaneously injected into 
the upper lip of mice just lateral to the nose. The 
time of the paw strokes directed to the injection 
area, called face rubbing, was recorded over a 
30-minute period, which was divided into 10 blocks 
of 3 min each, while the mice were in Plexiglas 
cages. In our study, cumulative data collected 
between 0 and 9 min post-formalin injection were 
grouped as phase 1 (0–9 min), whereas phase 2 
was composed of data collected between 12 and 
30 min post-formalin injection (the late phase).
Statistical analysis
Data are expressed as means±standard error of 
the mean (SEM) for each group. GraphPad Prism 4 
software (GraphPad Software, San Diego California, 
USA) was used for the statistical analyses. In 
WKH¿UVWVWDJHWKHWLPHFRXUVHHIIHFWVRIGUXJRU
vehicle treatment on face rubbing responses were 
evaluated by two-way repeated measure analysis 
of variance. Next, the averages of the period 
(0–9 min for Phase I and 12–30 min for Phase II) 
were calculated in each animals (bar graphs) and 
one way ANOVA were used to compare groups. A 
VLJQL¿FDQWHIIHFWRQWKHPDLQIDFWRUVZDVWDNHQ
as the criterion for progressing to post-hoc testing. 
The Bonferroni post-hoc test was used to compare 
WKH JURXSV 6WDWLVWLFDO VLJQL¿FDQFHZDV DFFHSWHG
as p<0.05.
RESULTS
Consistent with previous studies, following the 
formalin injection, a typical biphasic time course 
ZLWKDQHDUO\DQGVKRUWODVWLQJPLQ¿UVWSHULRGRI
activity (Phase I) was observed. This was followed 
by a 3-minute quiescent period. Then, a second, 
prolonged (12–30 min) tonic phase (Phase II) 
was observed (Figure 1A). The mean of the total 
face rubbing times were 96.29±1.6 seconds and 
61.33±2.41 seconds during Phase I (0–9 min) 
and Phase II (12–30 min), respectively (Figures 
1B and 1C). 
The two-way repeated measures of ANOVA 
analysis indicated that systemic administration of LP 
KDGVLJQL¿FDQWHIIHFWRQIDFHUXEELQJUHVSRQVHV
induced by formalin injection (F3,392=601.1, 
P<0.0001) (Figure 1A). While 1 mg/kg was 
ineffective, LP 44 doses of 5 and 10 mg/kg profoundly 
reduced face rubbing times at 3 and 6 min in Phase 
I (Figure 1A). Similar to Phase I, LP 44 at doses 
RIDQGPJNJVLJQL¿FDQWO\LQKLELWHGIRUPDOLQ
induced face rubbing responses at 15, 18, 21, and 
24 min in Phase II (Figure 1A). The mean of the 
total face rubbing times in Phase I, after LP 44 
injection at the doses of 5 and 10 mg/kg, were 
VLJQL¿FDQWO\UHGXFHGWRDQG
s (both p<0.001), respectively, in Phase I, which 
ZHUH VLJQL¿FDQWO\ GLIIHUHQW IURP FRQWURO JURXSV
(Figure 1B). LP 44 at the doses of 5 and 10 mg/
NJDOVRVLJQL¿FDQWO\UHGXFHGWKHWRWDOIDFHUXEELQJ
times to 41±1.08 and 7.3±0.7 s (both p<0.01), 
respectively, in Phase II, when compared with the 
control group (Figure 1C).
Similar to LP 44, systemic administration of LP 
KDGVLJQL¿FDQWHIIHFWRQIRUPDOLQLQGXFHGIDFH
rubbing responses in Phase I and II of the formalin 
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test (F3,392=213.77, P<0.0001) (Figure 2A). While 
LP 211 at a dose of 1 mg/kg did not alter formalin-
induced nociceptive face rubbing responses, LP 211 
GRVHVRIDQGPJNJVLJQL¿FDQWO\UHGXFHGIDFH
rubbing times at 3 and 6 min in Phase I (Figure 2A). 
The antinociceptive effects of LP 211 at the doses 
of 5 and 10 mg/kg were evident at 15, 18, 21, and 
24 min in Phase II when compared with the vehicle 
group (Figure 2A). The mean of face rubbing times 
at the 5 and 10 mg/kg of LP 211 pretreated groups 
in Phase I were reduced to 54.6±2.8 and 35.3±2.28 
seconds (both p<0.001, respectively, which were 
significantly different from the vehicle-treated 
group (Figure 2B). Similarly, LP 211 at doses of 
DQGPJNJDOVRVLJQL¿FDQWO\GHFUHDVHGIDFH
Figure 1- Time course of face rubbing activity induced 
by formalin injection into upper lip after systemic 
administration of LP 44, a selective 5-HT7 receptor 
agonist, or vehicle. Mice were pretreated with systemic 
administration of LP 44 (1, 5, and 10 mg/kg), 30 min prior 
to injection of 4% formalin (10 μl) into upper lip (A). Bar 
graphs represent the mean cumulative face rubbing time 
in s at Phase I (0–9 min) (B) and Phase II (12–30 min) 
&3GLIIHUHQFHVIURPFRQWUROJURXSV%RQIHUURQL
post hoc test)
A
B
C
A
B
C
Figure 2- Time course of face rubbing activity induced 
by formalin injection into upper lip after systemic 
administration of LP 211, a selective 5-HT7 receptor 
agonist, or vehicle treatment. Mice were pretreated with 
systemic administration of LP 211 (1, 5, and 10 mg/kg), 
30 min prior to injection of 4% formalin (10 μl) into upper 
lip (A). Bar graphs represent the mean cumulative face 
rubbing time in s at Phase I (0–9 min) (B) and Phase 
,, ± PLQ &  3 GLIIHUHQFHV IURP YHKLFOH
groups (Bonferroni post hoc test)
'(0ø5.$<$.$.*h1g0ù(1(/%g1&(/72581=6(<5(.0/$&ø9ø7$(/(232/'20'2ö58/$
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rubbing times during Phase II to 37.2±2.7 and 
17.88±2.94 s (both p<0.001), respectively, when 
compared with 5% DMSO-treated vehicle group 
(Figure 2C).
DISCUSSION
In this study, we have demonstrated that 
selective 5-HT7 receptor agonists elicit analgesic 
HIIHFWVRQRURIDFLDOSDLQ2XUGDWDFRQ¿UPSUHYLRXV
studies implying a role of 5-HT7 receptors in pain 
pathways.
The pathologic states of the teeth and the related 
structure induced acute orofacial pain is one of 
the most common pain, and it is well known that 
the orofacial region is heavily innervated by the 
trigeminal nerve. The orofacial formalin test is a 
recognized model of animal model of nociception 
related to trigeminal pain13. Formalin, as an 
electrophile irritant, induces tissue injury following 
its intracutaneous injection accompanied with 
prototypical a biphasic pattern of pain response6. 
The early phase is generally attributed to a direct 
effect of formalin on the nociceptors, while the late 
SKDVHDSSHDUVWREHGHSHQGHQWRQDQLQÀDPPDWRU\
reaction in the peripheral tissues and functional 
changes in spinal and brain stem spinal cord6. In 
the orofacial formalin test, face rubbing with the 
ipsilateral forepaw due to formalin injection into 
WKH XSSHU OLS KDV EHHQPHQWLRQHG DV D VSHFL¿F
nociceptive response18.
The serotonin in peripheral, spinal and supraspinal 
sites play in important role in the regulation of pain. 
)ROORZLQJWLVVXHLQMXU\RULQÀDPPDWLRQDYDULHW\
of mediator or modulators together with 5-HT are 
released that activate or sensitize nociceptors8. It 
has been hypothesized that 5-HT, functioning in 
FRPELQDWLRQZLWK RWKHU LQÀDPPDWRU\ RU DOJHVLF
PHGLDWRUVVLJQL¿FDQWO\PRGXODWHSDLQWUDQVPLVVLRQ
in peripheral and central nervous system. 5-HT 
modulates the pain via its receptors. Several 
different subtypes of 5-HT receptors have been 
suggested to be involved in pain transmission and 
pain modulation19. However, the multiplicity of 
5-HT receptors and the complex circuitry of pain 
transmission in peripheral and central nervous 
system complicates the analysis of subtypes of 5-HT 
receptors involved in the analgesia.
7KH +7 UHFHSWRU ZDV WKH ODVWO\ LGHQWL¿HG
serotonin receptor subtype. Our previous studies 
and other studies show that 5-HT7 receptor play 
a key role both in endogenous pain control and 
exogenously administered opioid and non-opioid 
analgesics drug action8,19,21. There are very few 
studies that examine the analgesic effects of 
selective 5-HT7 receptor agonist. Brenchat, et al.4,5 
(2010; 2012) reported that systemic administration 
of selective 5-HT7 agonists such as E-57431, AS-
19, and E-55888 blocked nerve injury-induced 
mechanical and thermal hyperalgesia in rat. In 
LQÀDPPDWRU\FDUUDJHHQDQPRGHO$OED\UDNHWDO1 
(2013) IRXQGWKDW$6HOLFLWVDQWLLQÀDPPDWRU\
action with concomitant blockade of the increase 
in 5-HT7 receptor expression induced by intrapaw 
injection of carrageenan.
7KHLPSRUWDQW¿QGLQJRIWKLVVWXG\LVWKDWWKH
intraperitoneal administration of the selective 
5-HT7 receptor agonists LP 44 or LP 211 produced 
an antinociceptive activity in both phases of the 
orofacial formalin test. This study expands the 
previous studies indicating the analgesic effects 
of 5-HT7 receptor agonist in other animal models 
RISDLQ DV WR WKHHI¿FDF\RI WKLV JURXSRI GUXJV
on orofacial pain. In line with previous reports 
GHVFULELQJDQWLLQÀDPPDWRU\DQGDQDOJHVLFDFWLRQ
of 5-HT7 receptor agonists under sensitization 
painful condition5, as expected, we found that LP 
44 and LP 211 reduced the nociceptive behavior in 
both phases of the orofacial formalin test. As CNS-
penetrant drugs, after systemic administration, LP 
44 and LP 211 can access peripheral, spinal, and 
supraspinal sites15. Thus, in the present study, the 
site of action underlying analgesic effects of 5-HT7 
agonist is unclear. Several studies demonstrated the 
involvement of descending serotonergic systems in 
modulating the orofacial nociception7. Interestingly, 
we reported the special important role of 5-HT7 
in the descending pain inhibitory pathways7,21. 
Neuroanatomical studies demonstrate the existence 
of 5-HT7 receptors in the substantia gelatinosa of 
the trigeminal subnucleus caudalis, which play a 
critical role in mediating orofacial nociception. Thus, 
it is possible to speculate that the antinociceptive 
action of LP 44 and LP 211 may be attributed to 
the activation of 5-HT7 receptors in the substantia 
gelatinosa neurons of the trigeminal nerve. 
Nevertheless, we cannot exclude the possibility that 
5HT2A receptors contribute to antinociception in the 
other brain areas and/or in the periphery. Further 
studies are needed to clarify the exact mechanism 
of analgesic action of 5-HT7 receptor agonist on 
orofacial pain.
CONCLUSION
In conclusion, our results suggest that targeting 
5-HT7 receptor might provide a new therapeutic 
tool for the treatment of orofacial painful conditions. 
+RZHYHU WKH HI¿FDF\ RI +7 UHFHSWRU DJRQLVW
should be tested in human orofacial pain models.
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